Icrucumab

Drug Profile

Icrucumab

Alternative Names: 18F1; IMC-18F1; LY 3012212; Monoclonal-antibody-18F1

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator ImClone Systems
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor receptor-1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer
  • Discontinued Colorectal cancer; Urogenital cancer

Most Recent Events

  • 03 Aug 2015 Phase-II development for Breast cancer is ongoing in USA and Canada
  • 01 Apr 2015 ImClone completes a phase II trial in Urogenital cancer (combination therapy; second-line therapy or greater) in Canada and USA (NCT01282463)
  • 20 Mar 2014 ImClone suspends enrolment in the phase II trial for Urogenital cancer (combination therapy; second-line therapy or greater) in Canada and US (NCT01282463)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top